Blocking an escape route on glioma cells helped mice fight the tumor
Original title: SWELL1 channel-mediated D-2HG export promotes immune evasion and metabolic fitness in IDH-mutant gliomas
How far along is this research?
This is a preprint. Other scientists have not checked it yet, so treat it as an early signal rather than an answer.
This was mostly done in mice and lab cells, not in people.
The short version
In mice, blocking a channel on tumor cells let the immune system attack the glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary better.
What was studied. Researchers looked at gliomas that have a change in the IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary gene. These tumors make a chemical called D-2HG, and the team tested how it gets out of tumor cells, using lab cells, mice, and stored human tumor samples.
What they found. The team found a channel called SWELL1 that lets D-2HG leave the tumor cell. When they removed or blocked this channel, much less D-2HG got out, and the immune system was no longer held back. A drug called dicumarol blocked the channel in mice. It slowed tumor growth, turned on immune T cells inside the tumor, worked well with an immune drug, and mice lived longer. In human tumor samples, higher levels of a related gene went along with a weaker immune response and shorter survival.
What this means, and what it doesn't
What it could mean: This points to a new way to help the immune system reach IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary gliomas. It also helps explain why these tumors are hard for the immune system to attack. For now it is a lead for future research, not a treatment option.
What it doesn't mean: This does not mean there is a new treatment. Most of this work was done in mice and in lab cells. The human part only looked at stored tumor samples, not at treating people. The drug has not been tested in people with glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary, so we do not know if it is safe or if it works in humans. This is not a cure, and it is many steps away from everyday care.
Source: bioRxiv (preprint), September 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.